Cronos rises as 75% topline growth powers Q3 beat
Cronos (CRON) stock rises as the company posts strong Q3 2026 financials with a 75% YoY revenue growth, driven by Israel and ...
Model output · Signal date 2026-11-09
Cronos Group Inc. (CRON) Stock Forecast Nov. 9, 2026
Analysis updated on Nov. 9, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
-17.0%
Spearman, 358 dates
Market Cap
$1.33B
small-cap · #3 of 28 peers
Summary
Cronos Group Inc. (CRON) stock forecast summary
Our AI scores Cronos Group Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Cronos Group Inc. is a small-cap company with a market capitalization of $1.33B. It ranks number 3 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast. Its Current Ratio of 12.71x is the highest of the 25 peers that report one. Its D/E Ratio of 0.07x is the lowest of the 16 peers that report one.
For CRON, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -17.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -13.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CRON included.
Price
CRON price chart and AI forecast
Cross-section · 2026-11-06
How CRON ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Cronos Group Inc. (CRON) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | CRON | Rank |
|---|---|---|
| Market Cap | $1.33B | 3/28 |
| P/B Ratio | 1.24x | 7/13 |
| EPS | $-0.05 | – |
| Book Value/Share | $2.91 | – |
| Revenue/Share | $0.74 | – |
| FCF/Share | $0.18 | – |
Profitability & Margins
| Metric | CRON | Rank |
|---|---|---|
| ROIC | 0.6% | 6/18 |
| Gross Margin | 35.3% | 15/21 |
| Operating Margin | 2.6% | 5/23 |
| EBT Margin | 22.1% | 2/23 |
| Tax Rate | -14.2% | – |
Financial Health
| Metric | CRON | Rank |
|---|---|---|
| Current Ratio | 12.71x | 1/25 |
| Quick Ratio | 11.91x | 1/23 |
| D/E Ratio | 0.07x | 16/16 |
| Financial Leverage | 1.12x | 16/16 |
| Interest Coverage | 42.0x | 2/21 |
| Working Capital | $792M | 2/25 |
Cash Flow
| Metric | CRON | Rank |
|---|---|---|
| Operating Cash Flow | $81M | 2/27 |
| Free Cash Flow | $65M | 2/12 |
| Capital Spending | -$16M | 8/12 |
| OCF Growth YoY | 272.8% | 2/10 |
| FCF/Sales | 24.1% | 1/12 |
| CapEx/Sales | 5.8% | 3/12 |
Operational Efficiency
| Metric | CRON | Rank |
|---|---|---|
| Asset Turnover | 0.23x | 15/15 |
| Receivables Turnover | 6.2x | 13/14 |
| Fixed Assets Turnover | 1.9x | 12/16 |
| Days Sales Outstanding | 59 days | 2/14 |
Income Statement
| Metric | CRON | Rank |
|---|---|---|
| Total Revenue | $272M | 7/17 |
| Operating Income | $7M | 3/26 |
| R&D Expense | $5M | 5/8 |
| SG&A Expense | $85M | 6/16 |
Dividend & Shareholder Information
| Metric | CRON | Rank |
|---|---|---|
| Shares Outstanding | 368M | – |
| EPS Growth | -131.2% | 5/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $859M | 71.7% of assets |
| Cash & Short-term Investments | $411M | 34.3% of assets |
| Accounts Receivable | $44M | 3.7% of assets |
| Inventory | $55M | 4.6% of assets |
| Total Liabilities | $73M | 6.1% of assets |
| Short-term Debt | $52M | 4.3% of assets |
Quarterly Financial Reports
CRON quarterly financials and insider trading
Industry Peers · Medicinal Chemicals & Botanical Products
Cronos Group Inc. (CRON) industry peers
Companies classified under the same SEC industry code as Cronos Group Inc. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CRON Cronos Group Inc. | $1.33B | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Where CRON sits on the market map
Life Sciences · Medicinal Chemicals & Botanical Products
News
Cronos Group Inc. (CRON) stock news
Cronos Group Reports 2026 Third Quarter Results
Detailed price information for Cronos Group Inc (CRON-Q) from The Globe and Mail including charting and trades.
Cronos Group Q3 Earnings Call Highlights
Cronos Group (NASDAQ:CRON) reported record third-quarter revenue, gross profit and adjusted EBITDA as cannabis sales grew in ...
FAQ
Cronos Group Inc. (CRON) stock forecast FAQ
What is the Cronos Group Inc. (CRON) stock forecast?
Our AI scores Cronos Group Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Cronos Group Inc. stock predictions?
For CRON, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -17.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -13.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cronos Group Inc. forecasts updated?
Cronos Group Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 9, 2026.
Which companies are Cronos Group Inc.'s industry peers?
30 issuers in our coverage, CRON included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.